(Reuters) – Pfizer Inc said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug, to be co-administered with HIV drug ritonavir, for the prevention of COVID-19 infection.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri)
